Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71335-0392

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-0392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine depicted, showing its molecular framework including a naphthalene group, a thiophene ring, and an amine group with a hydrochloride component.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time in days from randomization between placebo and duloxetine delayed-release capsules. The graph shows two lines: a dashed line for placebo and a solid line for duloxetine delayed-release capsules, illustrating relapse rates up to 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph depicting the proportion of patients with relapse over time in days from randomization. Two treatments are compared: Placebo, represented by a dashed line, and Duloxetine delayed-release capsules, shown as a solid line. The graph illustrates relapse trends over approximately 250 days, with the placebo group showing a higher proportion of relapse compared to the duloxetine group.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: DUL 60 mg BID, DUL 60 mg QD, DUL 20 mg QD, and Placebo, indicated by distinct markers. Improvement trends show higher patient percentages with DUL doses compared to placebo.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the relationship between percent improvement in pain from baseline (x-axis) and the percentage of patients improved (y-axis). The graph compares three treatments: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, with markers and lines indicating patient improvement percentages across different pain improvement thresholds.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for three groups: DUL 60mg twice daily, DUL 60mg once daily, and placebo. The x-axis shows increments of percent improvement in pain, and the y-axis shows the percentage of patients improved. Both duloxetine groups show higher patient improvement rates than placebo across the range.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: DULOXETINE (DUL) 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo, showing relative improvements in pain reduction across different percentiles.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved in pain from baseline between placebo and DULOXETINE DELAYED-RELEASE 60/120 mg once daily treatment groups. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines with markers illustrate outcomes for each group across the improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare Placebo and DUL 60 mg once daily, with percentages of patients improved decreasing as percent improvement increases from >0 to 100.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. Two curves are shown: one for placebo and one for DULOXETINE DELAYED-RELEASE 60/120 mg once daily, indicating patient response rates at various pain improvement thresholds.*

FDA Label Image

Label (Lbl713350392)

DULOXETINE DELAYED-RELEASE 30 mg capsule label by Bryant Ranch Prepack, featuring comparison to Cymbalta 30 mg capsule. Includes warnings such as 'May Cause Drowsiness' and storage instructions for room temperature 20°-25°C (68°-77°F). The label also displays the NDC number 71335-0392 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.